Last reviewed · How we verify
BPN14770/ zatolmilast
BPN14770 is a phosphodiesterase 4D (PDE4D) inhibitor that increases intracellular cAMP levels to enhance cognitive function and reduce neuroinflammation.
BPN14770 is a phosphodiesterase 4D (PDE4D) inhibitor that increases intracellular cAMP levels to enhance cognitive function and reduce neuroinflammation. Used for Cognitive impairment associated with schizophrenia, Alzheimer's disease.
At a glance
| Generic name | BPN14770/ zatolmilast |
|---|---|
| Sponsor | Tetra Discovery Partners |
| Drug class | Phosphodiesterase 4D (PDE4D) inhibitor |
| Target | PDE4D |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
By selectively inhibiting PDE4D, the drug prevents the breakdown of cyclic adenosine monophosphate (cAMP), leading to elevated cAMP levels in neurons and immune cells. This mechanism is thought to improve synaptic plasticity, enhance memory consolidation, and reduce pro-inflammatory cytokine production, making it potentially beneficial for cognitive disorders and neuroinflammatory conditions.
Approved indications
- Cognitive impairment associated with schizophrenia
- Alzheimer's disease
Common side effects
- Nausea
- Headache
- Diarrhea
- Vomiting
Key clinical trials
- A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome (PHASE2, PHASE3)
- Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS]) (PHASE2)
- An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome (PHASE3)
- A Study to Assess the Effects of BPN14770 on Rosuvastatin (PHASE1)
- A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BPN14770/ zatolmilast CI brief — competitive landscape report
- BPN14770/ zatolmilast updates RSS · CI watch RSS
- Tetra Discovery Partners portfolio CI